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Omecamtiv mercabil and blebbistatin modulate cardiac
contractility by perturbing the regulatory state of the
myosin filament
Thomas Kampourakis, Xuemeng Zhang, Yin-Biao Sun and Malcolm Irving
Randall Centre for Cell and Molecular Biophysics and British Heart Foundation Centre of Research Excellence, King’s College London, London, SE1
1UL, UK
Edited by: Harold Schultz & Bruce Smaill
Key points
 Omecamtivmecarbil and blebbistatin perturb the regulatory state of the thick filament in heart
muscle.
 Omecamtiv mecarbil increases contractility at low levels of activation by stabilizing the ON
state of the thick filament.
 Omecamtiv mecarbil decreases contractility at high levels of activation by disrupting the
acto-myosin ATPase cycle.
 Blebbistatin reduces contractility by stabilizing the thick filament OFF state and inhibiting
acto-myosin ATPase.
 Thick filament regulation is a promising target for novel therapeutics in heart disease.
Abstract Contraction of heart muscle is triggered by a transient rise in intracellular free calcium
concentration linked to a change in the structure of the actin-containing thin filaments that
allows the head or motor domains of myosin from the thick filaments to bind to them and induce
filament sliding. It is becoming increasingly clear that cardiac contractility is also regulated through
structural changes in the thick filaments, although the molecular mechanisms underlying thick
filament regulation are still relatively poorly understood. Here we investigated those mechanisms
using small molecules – omecamtiv mecarbil (OM) and blebbistatin (BS) – that bind specifically
to myosin and respectively activate or inhibit contractility in demembranated cardiac muscle
cells. We measured isometric force and ATP utilization at different calcium and small-molecule
concentrations in parallel with in situ structural changes determined using fluorescent probes on
the myosin regulatory light chain in the thick filaments and on troponin C in the thin filaments.
The results show that BS inhibits contractility and actin-myosin ATPase by stabilizing the OFF
state of the thick filament in which myosin head domains are more parallel to the filament axis.
In contrast, OM stabilizes the ON state of the thick filament, but inhibits contractility at high
intracellular calcium concentration by disrupting the actin-myosin ATPase pathway. The effects
of BS and OM on the calcium sensitivity of isometric force and filament structural changes
suggest that the co-operativity of calcium activation in physiological conditions is due to positive
coupling between the regulatory states of the thin and thick filaments.
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Introduction
Contraction of heart muscle is driven by transient inter-
actions between the myosin-containing thick filaments
and actin-containing thin filaments, coupled to the hydro-
lysis of ATP. Each heartbeat is triggered by a transient rise
in intracellular calciumconcentration followedby calcium
binding to the troponin complex in the thin filaments,
which in turn induces a structural change in the thin
filaments that allows the head or motor domain of myo-
sin to interact with actin (Gordon et al. 2000). Recently,
however, the canonical calcium–thin filament paradigmof
contractile regulation has been extended in both cardiac
and skeletal muscle by the emerging concept of regulatory
states of the thick filament. That concept originates from
structural studies of myosin and thick filaments from
myosin-regulated muscles, including vertebrate smooth
muscle (Wendt et al. 2001) and invertebrate skeletalmuscle
(Woodhead et al. 2005; Alamo, 2008; Pinto et al. 2012),
which are not regulated via their thin filaments, but by a
change in the structure of the thick filaments controlled
by phosphorylation of the myosin regulatory light chain
(RLC) (Brito, 2011) or by calcium binding to its essential
light chain (ELC) (Woodhead et al. 2013). In theOFF states
of those thick filaments, the myosin head domains are
prevented from either binding actin or hydrolysing ATP
by a network of intra- and inter-molecular interactions
that stabilize a conformation in which they are folded
back onto the myosin tails and the thick filament surface.
Activation of these myosin-regulated muscles releases the
myosin heads from this OFF state, making them available
for actin binding and ATP hydrolysis.
Multiple lines of evidence now indicate that this
regulatory transition in the thick filament has been
retained in muscle types and species that are regulated
by the calcium–thin filament regulatory pathway to work
in parallel with it (Linari et al. 2015; Fusi et al. 2016;
Kampourakis et al. 2016). In resting skeletal and cardiac
muscles of vertebrates, the myosin head domains lie in
helical tracks similar to those seen in the OFF state of
thick filaments from myosin-regulated muscles (Huxley
& Brown, 1967; Linari et al. 2015; Ait-Mou et al. 2016).
Many of the intra- and inter-molecular interactions that
stabilize that OFF structure are conserved in isolated
thick filaments from mammalian heart muscle (Zoghbi
et al. 2008; Al-Khayat et al. 2013). Biochemical studies of
vertebrate skeletal and cardiac muscle suggested that this
OFF structure corresponds to amyosin state with very low
ATP turnover called the ‘super-relaxed’ state (Hooijman
et al. 2011; Nogara et al. 2016b). Orientation-sensitive
probes on the myosin RLC in vertebrate skeletal and
cardiacmuscle cells show that thisOFF state is destabilized
by calcium activation, RLC phosphorylation, and by
increased sarcomere length (Kampourakis et al. 2015,
2016; Fusi et al. 2016). Finally, a recent X-ray diffraction
study on intact trabeculae suggested a stress-dependent
activation of the thick filament structure (Reconditi et al.
2017).
Together, the results from these diverse approaches
suggest that control of the structure of both the thin
and thick filaments is required for the physiological
regulation of cardiac contractility, including the strength
and kinetics of the heartbeat. Thick filament regulation is
likely to mediate the functional effects of phosphorylation
of the myosin regulatory light chain (RLC) and myosin
binding protein-C, and probably length-dependent
activation and the Frank-Starling relation (Colson et al.
2012; Ait-Mou et al. 2016; Kampourakis et al. 2016).
However, the molecular mechanisms underlying these
effects remain poorly understood. Here we investigated
those mechanisms using two small molecules that bind
specifically to cardiacmyosin: omecamtivmecarbil (OM),
a myosin activator in clinical trials for the treatment of
heart disease (Malik et al. 2011; Teerlink et al. 2011; Liu
et al. 2015), and (−)-blebbistatin (BS), a widely used
and well-characterized myosin inhibitor (Kovacs et al.
2004; Dou et al. 2007; Farman et al. 2008). Both OM and
BS bind to identified sites on the myosin head domain
with micromolar affinity (Fig. 1) but have no known
effects on other sarcomeric proteins. We determined
the effects of OM and BS on the regulatory state of the
thick filaments in cardiac muscle cells, in which the
native conformation and organization of the myofilament
sub-proteome is preserved, using polarized fluorescence
from bifunctional rhodamine probes on the myosin RLC
(Kampourakis et al. 2014, 2015) (Fig. 1). To check the
effects of OM and BS on the canonical calcium–thin
filament regulatory pathway, we carried out a similar set
of studies using a probe attached to troponin C. In both
cases we made measurements over a range of calcium
concentrations bracketing the physiological range, and
correlated the changes induced by OM and BS in thick
and thin filament structure with those on myocardial
force in the same preparation and on myofibrillar ATPase
activity.
The results show that the functional effects of OM
and BS on cardiac contractility can be understood in
terms of their effects on two regulatory pathways: the
previously established effects on the acto-myosin ATPase
pathway and a novel effect on thick filament-based
regulation controlling the availability of myosin heads
for contraction. OM stabilizes the ON state of the
thick filament and myosin states with bound ADP
(Malik et al. 2011; Liu et al. 2015; Rohde et al. 2017;
Swenson et al. 2017), whereas BS stabilizes myosin states
with bound ADP.Pi (Kovacs et al. 2004; Dou et al.
2007; Farman et al. 2008) and the OFF state of the
thick filament. Moreover, our results give new insights
into the physiological coupling between the regulatory
states of the thick and thin filaments and establish
C© 2017 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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mechanistic principles that may guide the development
of new myosin modulators with improved therapeutic
properties.
Methods
Animals and ethical approval
All animals were treated in accordance with the guidelines
approved by the UK Animal Scientific procedures Act
(1986) and EuropeanUnionDirective 2010/63/EU.Wistar
rats (male, 200–250 g) were killed by cervical dislocation
(Schedule 1 procedure in accordance with UK Animal
Scientific Procedure Act, 1986) and demembranated right
ventricular trabeculae were prepared as described pre-
viously (Sun et al. 2009). All procedureswere carried out in
accordance with the guidelines of the Animal Welfare and
Ethical Review Body (AWERB, King’s College London).
All animals have been kept with free access to food and
water prior to use.
Reagents
Omecamtiv mecarbil and (−)-blebbistatin were
purchased from Selleck (S2623) and Sigma (B0560),
respectively. Stock solutions were prepared in DMSO
(molecular biology grade, Sigma, D8418) and compound
purities were estimated to be >95% by RP-HPLC and ESI
mass spectrometry.
Preparation of BSR labelled cRLC and BR labelled cTnC
Bifunctional rhodamine labelled cTnC (BR-cTnC-E)
and bifunctional sulforhodamine labelled cRLC
(BSR-cRLC-E) were prepared as previously described
(Sun et al. 2009; Kampourakis et al. 2014; Kampourakis
& Irving, 2015).
Reconstitution of labelled cRLCs and cTnCs into
ventricular trabeculae
BR-cTnC-E was reconstituted into demembranated
trabeculae by overnight soak in relaxing buffer
(composition in mmol L−1: 25 imidazole, 15 disodium
creatine phosphate (Na2CrP), 78.4 potassium propionate
(KPr), 5.65 Na2ATP, 6.8 MgCl2, 10 K2EGTA, 1 DTT,
pH 7.1) containing 0.5 mg ml−1 of BR-cTnC-E at 4°C,
replacing about 80% of the endogenous cTnC (Sevrieva
et al. 2014). The maximal calcium-activated force after
reconstitution with BR-cTnC-Ewas 40.7± 2.5mNmm−2
(mean ± SEM, n = 11) at2.0 μm sarcomere length.
BSR-cRLC-E was exchanged into demembranated
trabeculae by extraction in CDTA-rigor solution
(composition in mmol L−1: 5 CDTA, 50 KCl, 40 Tris-HCl
pH 8.4, 0.1% (v/v) Triton X-100) for 30 min followed
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Figure 1. Labelling site of bifunctional sulforhodamine and binding sites of blebbistatin and omecamtiv
mecarbil in the myosin head domain and labelling site of bifunctional rhodamine on troponin
Chemical structures of (−)-blebbistatin (BS) and omecamtiv mecarbil (OM) are shown in A and B, respectively. C,
atomic model of squid myosin S1 in the detached conformation (PDB 1KK8). Bifunctional sulforhodamine (BSR)
attached to the RLC (green) E-helix is shown in pink, and BS and OM are shown in green and purple, respectively.
The myosin heavy chain (MHC; CD-catalytic domain; LCD-light chain domain) and essential light chain (ELC) are
shown in yellow and blue, respectively. The orientation of the BSR fluorescence dipole with respect to the motor
domain is indicated by red dashed double arrow. The model was created by superimposition of the catalytic
domains of myosin II bound to OM (PDB 4PA0) and BS (PDB 1YV3), with the catalytic domain of the squid myosin
S1. D, labelling site of bifunctional rhodamine (BR, pink) in the troponin complex (PDB 1J1D). Troponin C, troponin
I, troponin T and Ca2+ are shown in green, blue, yellow and grey, respectively. The BR probe is attached to the
troponin C E-helix. The orientation of the BR fluorescence dipole with respect to IT arm is indicated by red dashed
double arrow. [Colour figure can be viewed at wileyonlinelibrary.com]
C© 2017 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
34 T. Kampourakis and others J Physiol 596.1
by reconstitution with 40 μmol L−1 BSR-cRLC-E in
relaxing solution for 1 h, replacing 50% of the end-
ogenous cRLC (Kampourakis et al. 2014). The average
maximal calcium-activated force after cRLC exchange
(37.4± 3.2mNmm−2, mean± SEM, n= 9) was 85± 7%
of that before cRLC exchange.
Fluorescence polarization experiments
Composition of experimental solutions and activation
protocols were identical to those described previously
for fluorescence polarization experiments (Sun et al.
2009; Kampourakis et al. 2014; Kampourakis & Irving,
2015). Polarized fluorescence intensities weremeasured as
described previously for skeletal and cardiac muscle fibres
(Corrie et al. 1999; Brack et al. 2004; Sun et al. 2009;
Kampourakis et al. 2014). Fluorescence emission from
BSR-cRLC-E and BR-cTnC-E in trabeculae was collected
bya0.25NAobjectiveusing anexcitation lightbeam in line
with the emission path. The polarization of the excitation
and emitted beamswas set either parallel or perpendicular
to the trabecular axis, allowing determination of the order
parameter <P2> that describes the dipole orientations in
the trabeculae (Dale et al. 1999).
The sarcomere length of trabeculae was measured
by laser diffraction in relaxing solution prior to each
activation. Activating solution contained (in mmol L−1):
25 imidazole, 15 Na2CrP, 58.7 KPr, 5.65 Na2ATP, 6.3
MgCl2, 10 CaCl2, 10 K2EGTA, 1 DTT, pH 7.1. Each
activation was preceded by a 2-min incubation in
pre-activating solution (composition in mmol L−1: 25
imidazole, 15 Na2CrP, 108.2 KPr, 5.65 Na2ATP, 6.3MgCl2,
0.2 K2EGTA, 1 DTT, pH 7.1). Solutions with varying
concentrations of free [Ca2+] were prepared by mixing
relaxing and activating solutions using MAXCHELATOR
software (maxchelator.stanford.edu). Isometric force
and steady-state fluorescence polarization values were
measured once steady force had been established. The
dependence on force andorder parameters on free calcium
concentrationwasfitted todata from individual trabeculae
using non-linear least-squares regression to the modified
Hill equation:
F = Y0 + A ×
(
[Ca2+]nH/(−log10[pCa50]nH
+ [Ca2+]nH)
)
,
where pCa50 is the negative logarithm of [Ca2+]
corresponding to half-maximal change in F, nH is the Hill
coefficient, Y0 is the baseline, and A is the amplitude (for
normalized force data: Y0 = 0 and A = 1). Trabeculae
which showed a decline in maximal calcium-activated
force of more than 15% after the pCa titrations were
discarded.
Compound stocks were directly diluted in physiological
buffers used for trabeculae experiments. The DMSO
concentration was typically not more than 0.2% (v/v)
and control experiments showed that addition of 0.2%
(v/v) DMSO had no effect on calcium sensitivity or
cooperativity of force and probe orientation. Prior to the
experiments, demembranated rat ventricular trabeculae
were incubated in relaxing solution containing the
appropriate concentration of either omecamtiv mecarbil
or blebbistatin for 25–30 min at 22°C.
Preparation of cardiomyofibrils and ATPase activity
measurements
Cardiomyofibrils (CMFs)were prepared byhomogenizing
freshly frozenventricular tissue samples inmyofibril buffer
(composition in mmol L−1: 20 imidazole pH 7.4, 75 KCl,
2MgCl2, 2 EDTA, 1 DTT, 1% (v/v) Triton X-100, protease
inhibitor cocktail (Roche), PhosStop cocktail (Roche))
followed by centrifugation at 5000 g for 5 min at 4°C.
CMFs were washed and homogenized three more times in
the same buffer without Triton X-100.
CMFs were washed three times in ATPase assay buffer
(composition in mmol L−1: 20 MOPS pH 7.0, 35 NaCl,
5 MgCl2, 1 EGTA, 1 DTT) with varying concentrations
of CaCl2 (pCa 9 to pCa 4.3) and the CMF concentration
adjusted to 0.5 mg ml−1 (Utter et al. 2015). For
ATPase measurements at activating Ca2+ concentrations,
CMFs were partially crosslinked with 5 mmol L−1
N-hydroxysuccinimide (NHS) and 2mmol L−1 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide hydrochloride
(EDC) in myofibril buffer on ice for 90 min (Herrmann
et al. 1993). The crosslinking reaction was stopped
by the addition of 25 mmol L−1 glycine pH 8.0 and
10 mmol L−1 DTT for 30 min on ice and CMFs processed
for experiments as mentioned above. Chemical cross-
linking prevents CMFs from shortening during calcium
activation. Reactions were started by the addition of
2.5 mmol L−1 ATP and samples taken at the indicated
time points were quenched with 0.5 volumes ice cold
25% (w/v) TCA solution. Samples were kept on ice at all
times, diluted with double-deionized water and inorganic
phosphate content measured using the malachite green
assay according to manufacturer’s instructions (Sigma,
MAK030).
Statistical analysis
All data sets were normally distributed as assessed by
Shapiro-Wilk test (P > 0.05). Statistical significance of
difference between groups was assessed with a one-way
ANOVA followed by Turkey’s post hoc test. Paired data sets
were analysedby a two-tailedpairedStudent’s t test.Details
of significance levels are shown in the figure captions.
C© 2017 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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Results
Effects of omecamtiv mecarbil and blebbistatin
on isometric force production in rat ventricular
trabeculae
Although omecamtivmecarbil (OM) is generally regarded
as anactivatorof cardiacmyosin, andOMincreases cardiac
outputunder therapeutic conditions (Malik et al. 2011), its
effects depend strongly on calcium concentration [Ca2+]
and are inhibitory at high [Ca2+] (Fig. 2A). OM does
activate isometric force in isolated trabeculae both at very
low [Ca2+] (pCa 9, Fig. 2, black circles), and also around
1 μmol L−1 [Ca2+], close to the physiological value at
systole under basal conditions. The largest effects were
observed at micromolar concentrations of OM, and the
increases in isometric force were statistically significant
(P < 0.05) for [OM] = 1 μmol L−1 and higher. Iso-
metric force was lower at higher OM concentrations, as
reported previously for isolated rat cardiomyocytes (Nagy
et al. 2015). In contrast, OM strongly inhibited force
production at full calcium activation (pCa 4.3, Fig. 2A,
open circles) with an EC50 of 2.12 ± 0.17 μmol L−1
(mean ± SEM, n = 3), in agreement with its reported
affinity for isolatedβ-cardiacmyosinS1 (Malik et al. 2011).
Interestingly, the inhibition of maximal active isometric
force has not been observed in human myocardium for
[OM]  10 μmol L−1 (Swenson et al. 2017). OM slowed
the rate of isometric force development at all [Ca2+] (data
not shown), consistent with previous studies on isolated
rodent cardiomyocytes (Nagy et al. 2015).
In contrast, blebbistatin (BS) inhibited isometric force
in ventricular trabeculae at all [Ca2+] (Fig. 2B). At full
calcium activation (pCa 4.3) force inhibition by BS had
an EC50 of 3.17 ± 0.43 μmol L−1, consistent with the
binding affinity of BS for isolated skeletal myosin S1 in
the ADP.Pi state (Kovacs et al. 2004) and with the EC50
for force inhibition by BS in mouse papillary muscle
(2.8μmolL−1) (Dou et al. 2007). BS also reducedpassive
force slightly at pCa 9, with a similar EC50 (Fig. 2B). BS
did not significantly affect the apparent rate of isometric
force development (data not shown).
Omecamtiv mecarbil and blebbistatin induce changes
in thick filament structure
We determined the effect of OM and BS on thick
filament structure in trabeculae using a bifunctional
sulforhodamine (BSR) probe attached to the myosin
regulatory light chain (cRLC, Fig. 1). The probe was
cross-linked to the cRLC E-helix (BSR-cRLC-E), which
is almost parallel to the long axis of the myosin light
chain domain (LCD) (Kampourakis et al. 2015). The
orientation of the RLC region of the myosin heads with
respect to the thick filament axis can be determined from
the polarization of the fluorescence from this probe. The
results are expressed in termsof the order parameter<P2>
(Dale et al. 1999), which would be +1 if all the probe
dipoles (red arrow in Fig. 1) are parallel to the trabecular
or thick filament axis, and −0.5 if they are perpendicular.
<P2> decreases when trabeculae are activated, indicating
a more perpendicular orientation of the cRLC E-helix and
LCD with respect to the thick filament axis, and a more
ON state of the thick filament.
Incubating relaxed trabeculae in OM produced a
decrease in <P2> for the cRLC E-helix probe (Fig. 3C,
pCa 9, filled circles), with an EC50 of 1.12± 0.09μmol L−1
(mean± SEM, n= 4), and aHill coefficient of 1.75± 0.14
(mean ± SEM, n = 4), indicating positive cooperativity.
The maximum effect of OM on <P2> was 70% larger
than that of maximal calcium activation of ventricular
trabeculae in the absence of drug. OM also reduced
<P2> during maximal calcium activation (pCa 4.3, open
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Figure 2. Concentration dependence of the effects of omecamtiv mecarbil (OM) and blebbistatin (BS)
on isometric force development of native demembranated rat right ventricular trabeculae
A and B, dose–response curves for OM and BS, respectively, on passive force at pCa 9 (filled circles), and active
force at pCa 6 (grey circles) and pCa 4.3 (open circles). Isometric forces were normalized to that at pCa 4.3 in the
absence of drugs (T0). Values indicate means ± SEM (n = 3). BS reduced passive force at pCa 9 (filled circles) by
60% with an EC50 of 2.3 ± 0.9 µmol L−1.
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circles), with a similar EC50 (1.03 ± 0.14 μmol L−1).
These EC50 values are similar to those for active isometric
force of native and BSR-cRLC-E exchanged trabeculae
(Figs 2A and 3A), and to that of the ATPase rate of
isolated β-cardiac myosin (Malik et al. 2011). However,
whilst addition of OM was associated with a more ON
thick filament (a lower <P2> indicating that the LCD of
the myosin heads is more perpendicular to the filament
axis) in both relaxing and activating conditions (Fig. 3C),
it had opposite effects on isometric force in these two
conditions (pCa 9 and pCa 4.3; Fig. 3A). Moreover, there
was no sign in the <P2>–[OM] relation (Fig. 3C) of
the bell-shaped dose–response relation of force at low
[Ca2+] (pCa 9, Figs 2A and 3A). Thus, althoughOMbinds
stoichiometrically to a single site on the myosin catalytic
domain (CD) (Malik et al. 2011;Winkelmann et al. 2015),
its effect on contractility, in contrast with that on cRLC
E-helix orientation, depends strongly on [Ca2+].
In contrast to OM, incubation of trabeculae in BS
increased <P2> for the BSR-cRLC-E probe, indicating
that BS stabilizes the OFF conformation of the thick
filament in which the LCD of the myosin heads is
more parallel to the filament axis (Kampourakis et al.
2014, 2015). BS increased <P2> at both low and high
[Ca2+], with EC50 values of 2.91 ± 0.78 μmol L−1 and
2.33 ± 0.38 μmol L−1, respectively (Fig. 3D), similar to
those for passive and active force in the same trabeculae
(Fig. 3B) and in trabeculae containing the native cRLC
(Fig. 2B). The change in cRLC E-helix orientation
associated with calcium activation was attenuated by BS
(Fig. 3D), and became insignificant at [BS]= 5μmol L−1,
despite the fact that active isometric force (T/T0) at this
BS concentration is still 31 ± 7% (mean ± SEM, n = 4)
of its control value (Fig. 3B).
Effect of omecamtiv mecarbil and blebbistatin on
cardiomyofibrillar ATPase activity
To better understand the mechanisms underlying the
ability of OM to either activate or inhibit isometric force
depending on the conditions, we measured the ATPase
activity of freshlyprepared rat ventricular cardiomyofibrils
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Figure 3. Concentration dependence of the effect of omecamtiv mecarbil and blebbistatin on force and
myosin head orientation measured from BSR-cRLC-E exchanged trabeculae
A and C, effect of OM on isometric force (A) and order parameter <P2> (C) for BSR-cRLC-E at pCa 9 (closed
circles) and pCa 4.3 (open circles). B and D, concentration-dependent effect of BS on isometric force (B) and order
parameter <P2> (D) at pCa 9 (closed circles) and pCa 4.3 (open circles). Note that the effects of OM and BS
on isometric force are identical to those for native, untreated trabeculae (Fig. 1). Values indicate means ± SEM
(n = 4). The pictograms indicate the orientation of BSR probe (grey double arrow) and myosin heads with respect
to the thick filament axis (black thick arrow). The angular changes are exaggerated for clarity.
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at 50 μmol L−1 OM, a concentration at which the thick
filament structure is fully ON, but calcium-activated
force is largely inhibited (Fig. 3). For comparison, we
also measured the effects on myofibrillar ATPase of
50μmolL−1 BS, a concentration that induces theOFFstate
of the thick filament and also inhibits calcium-activated
force.
Addition of 50 μmol L−1 OM inhibited the cardio-
myofibrillar ATPase rate at both low (pCa 9) and high
[Ca2+] (pCa 4.3) (Fig. 4, grey bars). OM reduced
the ATPase of relaxed myofibrils by about 24%, and
the ATPase rate of isometrically contracting myo-
fibrils at pCa 4.3 by about 37% with an EC50 of
1.3 μmol L−1 (Fig. 4D), consistent with its effects on
thin filament-activated ATPase activity of isolated porcine
heavy meromyosin (HMM) (Liu et al. 2015) and the
actin-activated ATPase activity of recombinant human
β-cardiac myosin S1 (EC50 0.5 μmol L−1) (Swenson
et al. 2017). Thus, although addition of 50 μmol L−1
OM at low and high [Ca2+] induces a more ON thick
filament structure (Fig. 2C) and activates isometric
force at low [Ca2+] (Figs 2A and 3A), it inhibits the
ATPase under the same conditions. Interestingly, the
fractional inhibition of myofibrillar ATPase at maximal
calcium activation (37%) is much less than that of
isometric force (90%). However, OM increases the
ATPase activity of cardiac myofibrils at intermediate levels
of activation (pCa 6) (Fig. 4B), similar to its effect on
isometric force under the same conditions (Fig. 2A).
Moreover, the similar EC50 forOM’s effect onmyosin head
orientation (Fig. 3C) andATPase activity suggests coupling
between biochemical and structural states of myosin.
Addition of 50 μmol L−1 BS reduced the ATPase rate
of cardiac myofibrils at all [Ca2+] tested by 60–90%, as
expected from the inhibitory effects of BS on isometric
force and thick filament structure (Fig. 3B and D).
Omecamtiv mecarbil and blebbistatin have
contrasting effects on the calcium sensitivity of
isometric force and thick filament structure
The activating effect of OM on isometric force at low and
intermediate [Ca2+] implies that it sensitizes the myo-
filaments to calcium, an effect that might be associated
with the more ON thick filament structure induced by
the drug, although in apparent contradiction with its
inhibitionofmyofibrillarATPase athigh [Ca2+].Tounder-
stand better the action of OM on the calcium sensitivity
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of contractile activation, we determined the effect of a
clinically relevant concentration of OM of 1 μmol L−1,
which is within the range of plasma concentrations
measured during clinical trials (0.25–2.5 μmol L−1)
(Cleland et al. 2011; Teerlink et al. 2011, 2016; Greenberg
et al. 2015), on the [Ca2+] dependence ofmyocardial force
and thick filament structure in the physiological range.
As before we contrasted the effects of OM with those
of BS, at a concentration (5 μmol L−1) that induced a
largely OFF state of the thick filament, but left enough
isometric force to allow us to determine its [Ca2+]
dependence.
At 1 μmol L−1 OM had a large effect on the [Ca2+]
dependence of isometric force (Fig. 5A, open circles),
particularly in the physiologically relevant range around
pCa 6. The pCa required for half-maximal force (pCa50,
Fig. 6A, Table 1) increased from5.56± 0.01 (mean± SEM,
n = 9) in the absence of OM to 5.90 ± 0.03 in its pre-
sence, but the Hill coefficient (nH, Fig. 6B), a measure of
the cooperativity of calcium activation, decreased from
6.85 ± 0.65 to 2.78 ± 0.12. The effects of 1 μmol L−1
OM on the calcium sensitivity of thick filament structure
as reported by the cRLC E-helix probe were even larger
(Fig. 6B). pCa50 for probe orientation increased from
5.56 ± 0.01 (the same as the value for force in the absence
of OM) to 6.11± 0.06, and nH decreased from 8.41± 0.66
to 2.61 ± 0.17. The [Ca2+] dependence of the orientation
of the cRLC E-helix probe in the absence of OM is similar
to that reported previously for a BSR probe on the N-lobe
of the cRLC (Kampourakis et al. 2014).
In marked contrast with the effects of OM, 5 μmol L−1
BS decreased pCa50 for normalized force by 0.25 pCa
units (Fig. 5A, inverted triangles; Fig. 6A). BS, like OM,
reduced nH to 2.5 (Fig. 6B; Table 1). Thick filament
structure as reported by the RLC probe was independent
of [Ca2+] at 5μmolL−1 BS (Figs 5B and3D). Strikingly, the
[Ca2+] dependences of force and thick filament structure
in the presence of OM and BS (Fig. 5A and B; open
circles, inverted triangles) bracket the control relationship
(filled circles). OM produces a more ON thick filament
structure and sensitizes force to calcium; BS does the
opposite. However both OM and BS greatly reduce the
co-operativity of calcium activation (Fig. 6B), suggesting
that the steep co-operativity in control conditions requires
a thick filament structure that is finely poised between the
OFF and ON states.
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Effects of omecamtiv mecarbil and blebbistatin on
thin filament activation
The correlation described above, between the changes in
thick filament structure induced by OM and BS and the
calcium dependence of active force mediated by Ca2+
binding to troponin in the thin filaments, suggests that
the activation state of the thin filament is sensitive to
that of the thick filament (Kampourakis et al. 2016). To
further investigate that possibility we used a bifunctional
rhodamine (BR) probe on the E-helix of cardiac troponin
C (cTnC) in the so-called ‘IT arm’ of troponin to
determine directly the effects of OM and BS on the
activation state of the thin filament (Sun et al. 2009;
Kampourakis et al. 2014).
The effects of OM (1 μmol L−1) and BS (5 μmol L−1)
on isometric force in trabeculae containing BR-cTnC-E
(Fig. 5C)were similar to those reported above.However, in
contrast to their effects on the activation state of the thick
filament, neither OM nor BS changed the activation state
of the thin filament as reported by the cTnC E-helix probe
in relaxing conditions (pCa 9) (Fig. 5D). Since 1μmol L−1
OM activates isometric force in these conditions (Figs 2A
and3A), this is a surprising result. To check it,wemeasured
the orientation of the cTnC E-helix probe at a series
of OM concentrations up to 50 μmol L−1 and found
no effect of OM on probe orientation in either relaxing
conditions (pCa 9) or during maximal calcium activation
(pCa 4.3) (crosses in Fig. 5D), in contrast with its effect on
thick filament structure in the same conditions (Fig. 3C).
Moreover, lattice compression by 1–3% (w/v) dextran had
no significant effect on probe orientation in the presence
of 1 μmol L−1 OM at either pCa 9 or pCa 4.3 (data not
shown). Neither activation of isometric force by OM at
pCa 9 nor inhibition of force at pCa 4.3 are mediated by
changes in thin filament structure as reported by the TnC
E-helix probe.
At 5 μmol L−1 BS did reduce the level of thin filament
activation at pCa 4.3 reported by the cTnC E-helix probe
by 30% (Fig. 5D and Table 1), in agreement with pre-
vious results during almost complete force inhibition at
25 μmol L−1 BS (Sun et al. 2009). However, increasing
[BS] to 25 μmol L−1 in the present experiments had
no further effect on cTnC E-helix probe orientation at
pCa 4.3 (squares in Fig. 5D), despite the further inhibition
of isometric force from 25% to 1%. Thus, as in the
case of OM, the effects of BS on isometric force are not
simply related to thin filament structure as monitored by
the TnC E-helix probe.
The calcium sensitivity (pCa50) of the change in thin
filament activation reported by the cTnC E-helix probe
was increased by 1 μmol L−1 OM and decreased by
5 μmol L−1 BS (Figs 5D and 6A), consistent with the
hypothesis that the activation state of the thin filament
is sensitive to that of the thick filament at physiological
C© 2017 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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[Ca2+] (Kampourakis et al. 2016). OM (1 μmol L−1)
reduced the steepness (nH) of the calcium dependence
of TnC E-helix probe orientation to 2.5 (Fig. 6B), similar
to the effect on force and thick filament structure reported
by the cRLC probe (Figs 5B and 6B), but BS had a smaller
effect on nH for TnC E-helix probe orientation, which
was still 4.2 in the presence of 5 μmol L−1 BS (Fig. 6D,
Table 1). The effect of 1 μmol L−1 OM on pCa50 for TnC
probe orientation was significantly smaller than that for
force, in contrast with its effect on pCa50 for the cRLC
probe in the thick filament, which was larger than that for
force (Fig. 6A).
Discussion
OM and BS stabilize ON and OFF states of the thick
filament respectively in the absence of Ca2+
In this study we have for the first time established
detailed structure–function relationships for OM and
BS that integrate functional, biochemical and structural
measurements in the native environment of the intact
muscle lattice. Our results establish a novel mechanistic
basis for the modulation of myosin function via thick
filament-based regulation and coupling between the
regulatory states of the thick and thin filaments, and
suggest how those mechanisms contribute to the normal
physiological regulation of contractility in the heart.
We have interpreted the antagonistic effects of OM
and BS on the orientation of the myosin cRLC in
terms of structural OFF and ON states of the thick
filament. Those states were monitored using a probe that
has its fluorescence dipole parallel to the cRLC E-helix
(Kampourakis et al. 2014, 2015, 2016) (Fig. 1). This probe
ismoreparallel to the thickfilament axis in themyosinOFF
state or interacting heads motif (IHM) observed in EM
reconstructionsof isolated thickfilaments (Al-Khayat et al.
2013) and this orientation is measured as a higher value
of the order parameter <P2>. The results from this cRLC
E-helix probe showed that, at very low [Ca2+] (pCa 9),OM
induces a more ON state of the thick filament, whereas
BS induces a more OFF state (Fig. 3). This conclusion is
consistent with the contrasting effects of OM and BS on
the ATPase of isolatedmyosin head domains (Kovacs et al.
2004;Malik et al. 2011; Liu et al. 2015; Swenson et al. 2017);
OM accelerates the rate of release of inorganic phosphate
(Pi) from the myosin.ADP.Pi intermediate, whereas BS
inhibits it. Thus OM increases the fraction of myosins
in the ADP state that can bind strongly to actin and
generate force, whereas BS increases the fraction in the
weak-binding or low-force ADP.Pi state. These two states
are associated with different conformations of the myo-
sin head domain, the switch-2 open and closed states,
respectively. Moreover, the ADP.Pi or switch-2 closed
conformation is required for the OFF structure of the
thick filament (Xu et al. 1999; Zoghbi et al. 2004; Zhao
et al. 2008). Furthermore, the quantitative effect of both
compounds (OM and BS) is most likely modulated by
post-translational modifications of proteins associated
with regulatory structural transitions in the thick filament,
e.g. phosphorylation of cRLC and cMyBP-C.
The biochemical correlate of the myosin OFF state has
been described for both skeletal and cardiac muscle, and
termed the super-relaxed state (SRX), characterized by a
population ofmyosin headswith ultra-lowATPase activity
(Stewart et al. 2010; Hooijman et al. 2011). Structural
and functional studies in isolated skeletal muscle fibres
(Wilson et al. 2014) and human myocardium (Tang
et al. 2016) suggested that BS and its derivatives stabilize
the SRX.
Consistent with these structural and biochemical
correlations, OM and BS have opposite effects on iso-
metric force at pCa 9; OM activates force and BS inhibits it
(Fig. 2). The ability of OM to activate force in the absence
of calcium, when the thin filament would normally be
switched OFF, implies that myosin heads with bound OM
can bind to thin filaments and displace tropomyosin to its
ONposition in the absence of calciumbinding to troponin
6.2
A B
6.0
5.8
5.6
5.4
5.2
Control 1 µmol/L OM 5 µmol/L BS Control 1 µmol/L OM 5 µmol/L BS
T/T0 RLC-E
T/T0 TnC-E
<P2> RLC-E
<P2> TnC-E
*
***
***
***
***
***
***
***
***
pC
a 5
0
n H
* ***
0
2
4
6
8
10
Figure 6. Summary of force–pCa (circles) and <P2>–pCa (squares) parameters
A and B, pCa50 (A) and nH values (B) for BSR-cRLC-E (open symbols) and BR-cTnC-E (closed symbols) exchanged
trabeculae. Means ± SEM (n = 4–9). Statistical significance of differences from the control group was assessed by
a one-way ANOVA with Turkey’s post hoc test: ∗P < 0.05; ∗∗∗P < 0.001.
C© 2017 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
J Physiol 596.1 Myosin filament regulation in heart muscle 41
(Fig. 7), consistent with the decreased rate of relaxation
observed in isolated cardiomyocytes in the presence ofOM
(Nagy et al. 2015).
However, the orientation of the cTnC-E helix probe
did not change when the thick filament and isometric
force were activated by OM in these conditions (Fig. 5),
in marked contrast to the large change in cTnC E-helix
probe orientation associated with calcium activation and
the even larger change associated with activation by rigor
myosin heads (Sun et al. 2009). Although all these thin
filament activation pathways presumably involve a change
in the azimuthal position of tropomyosin, activation by
OM appears to work through a distinct inter-filament
signalling pathway which is not directly coupled to a
change in the cTnC E-helix orientation. Activation byOM
at pCa 9 is also associated with a modest decrease in the
myofibrillar ATPase activity, in contrast with the15-fold
increase associated with calcium activation (Fig. 4), and
this is presumably associated with direct inhibition of
ATPase in myosin heads with bound OM.
Effects of OM and BS in the presence of calcium reveal
regulatory coupling between thick and thin filaments
The competing activating and inhibitory effects of OM
are modified in the presence of calcium. At full calcium
activation (pCa 4.3) OM strongly inhibits isometric force
(Figs 2A and 3A) and cross-bridge kinetics (Mamidi et al.
2015), and modestly reduces myofibrillar ATPase (Fig. 4),
despite inducing a more ON state of the thick filament
(Fig. 3C). These inhibitory and activating effects have the
same EC50, suggesting that both are the consequence of
OMbinding toa single siteon themyosinhead to stabilize a
myosin.ADP state (Rohde et al. 2017; Swenson et al. 2017).
Similar to results in the absence of calcium discussed
above,OMbinding tomyosin does not alter the regulatory
state of the thin filament as reported by the TnC E-helix
probe at pCa 4.3 (Fig. 5). As in that case, we conclude
that the competing activating and inhibitory effects of
OM at pCa 4.3 are mediated by changes in thick filament
structure and actin-activatedmyosin ATPase, respectively.
The activating effect dominates contractility at low [OM]
and [Ca2+], probably as a result of the co-operativity
of thick filament activation, with a Hill co-efficient for
[OM] dependence of 1.75, whereas the inhibitory effect
dominates at higher [OM] and [Ca2+], when both thick
and thin filaments are largelyON. These competing effects
may be responsible for the bell-shaped dependence of iso-
metric force on [OM] at low and intermediate [Ca2+]
(Figs 2A and 3A).
BS, in contrast, stabilizes the OFF structure of the thick
filament and inhibits force production (Fig. 3) and myo-
fibrillar ATPase in all conditions studied. The effects of
BS on active force and thick filament structure have the
same EC50, consistent with both being associated with
stabilization of the ADP.Pi state of the myosin head pre-
sumably in the pre-power-stroke conformation (Alamo
et al. 2017), reducing ATP turnover and promoting the
OFF structure of the thick filament. BS had no effect on
the level of activation of the thin filament as reported
by the cTnC E-helix probe at pCa 9, but reduced its
activation level at pCa 4.3 (Fig. 5), indicating positive
coupling between the activation states of the thick and
thin filaments in the presence of calcium.
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and BS on myofilament Ca2+ activation
Under control conditions in the absence of any
drug, normalized myocardial force shows a steep
dependence on [Ca2+] (continuous line). OM
induces a perpendicular myosin head orientation,
activates the thick filament in the absence of Ca2+
and stabilizes the myosin.ADP state (left). Thick
filament activation by OM increases myocardial
calcium sensitivity of force, but decreases
cooperativity of activation (dashed-dotted line). In
contrast, BS stabilizes the thick filament OFF state
characterized by a parallel myosin head orientation
in the ADP.Pi state (right), and decreases calcium
sensitivity and cooperativity of force (dashed line).
[Colour figure can be viewed at
wileyonlinelibrary.com]
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Although OM does not affect the regulatory state of
the thin filament reported by the cTnC E-helix probe at
either pCa 9 or 4.3, at intermediate [Ca2+] in the physio-
logical range it switches ON the thin filament as well as
the thick filament, and BS switches OFF both filaments
(Figs 5 and 6). Both small molecules can perturb the
normal coupling between the regulatory states of the
thick and thin filaments, as shown by the altered Ca2+
dependence of structural changes in the myofilaments
and force development. In the absence of either OM
or BS, activation of the thick and thin filaments and
isometric force have similar but not identical [Ca2+]
dependence; calcium sensitivity (pCa50) is close to 5.5,
and Hill coefficients (nH) are greater than 5.5 (Fig. 6;
Table 1). However, nH for thick filament structure is
significantly higher than that for thin filament structure or
force, as reported previously for a different probe on the
N-lobe of the cRLC (Kampourakis et al. 2016); calcium
activation of the thick filament is more co-operative
than that of the thin filament. Co-operativity of the thin
filament is likely to be associated with end-to-end joining
between tropomyosin regulatory units (Gordon et al.
2000); that of the thick filament to the multiple inter-
and intra-molecular interactions that stabilize the thick
filament OFF state (Al-Khayat et al. 2013).
The effects of BS and OM reported above have
implications for the roles of thin and thick filament
co-operativity duringnormal contractile activation.When
the thick filament is locked in its OFF state by 5 μmol L−1
BS, so that its structure becomes independent of [Ca2+]
(Fig. 5B), calcium activation becomes less co-operative –
nH for force is reduced from more than 6 to less than 3,
and calcium sensitivity pCa50 is reduced by about 0.25
pCa units (Table 1). Pushing the thick filament towards
the ON state with 1 μmol L−1 OM also reduces nH to less
than 3, but increases calcium sensitivity of force by about
0.3 pCa50 units (Figs 5 and 6).
These effects suggest that the intrinsic co-operativity of
the thin filament activation is low, and that its calcium
sensitivity depends on the regulatory state of the thick
filament (Fig. 7). When the thick filament is OFF, pCa50
is about 5.3 (as in the presence of BS; Fig. 7, dashed line);
when the thick filament isON, pCa50 is about 5.5 or higher
(as in the presence of OM; Fig. 7, dashed-dotted line). In
physiological conditions, the thick filament is OFF at low
[Ca2+], and no active force is produced at pCa > 5.9. At
slightly higher [Ca2+], around pCa 5.7, the thin filament
starts to be activated and this starts to activate the thick
filament, which in turn increases the calcium sensitivity of
the thin filament (Fig. 7, red shaded area). The net result
of this inter-filament coupling is to produce a very steep
dependence of the activation state of both filaments and
isometric force on [Ca2+] (continuous line).
Taken together, our results suggest that the force–
calcium relation of cardiac muscle is controlled by
three regulatory pathways working in parallel: calcium
activation of the thin filament, the regulatory state of
the thick filament and intermediates in the acto-myosin
ATPase pathway.
This scheme also provides a qualitative explanation for
the effects of other interventions that affect the regulatory
state of the thick filament, like RLC phosphorylation
and increased sarcomere length (Kampourakis et al.
2016), on the calcium sensitivity of the thin filament
and isometric force. Moreover, hypertrophic and dilated
cardiomyopathy mutations have been shown to alter the
calciumdependence ofmyofilament activation in a similar
manner to OM and BS (Spudich, 2014), implicating
disturbed inter-filament coupling in the aetiology of
cardiomyopathy-associated heart failure. An uncoupling
between the regulatory structural changes in the thick
filament and force generation similar to that produced by
OM has been recently suggested as a mechanism under-
lying the hyper-contractility associated with hypertrophic
cardiomyopathy mutations in the myosin head domain
(Alamo et al. 2017; Nag et al. 2017; Trivedi et al. 2017).
The molecular mechanisms responsible for coupling
between the regulatory states of the thin and thick fila-
ments remain to be elucidated, but candidatemechanisms
would include binding of myosin heads to thin filaments
(Gordon et al. 2000) and binding of the N-terminus of
cMyBP-C to the thin filaments (Pfuhl & Gautel, 2012;
Kampourakis et al. 2014). Binding of myosin heads to
thin filaments stabilizes their ON state by preventing
tropomyosin moving back to its OFF position, so an
ON thick filament can promote an ON thin filament.
Similarly, binding of the N-terminus of cMyBP-C to the
thin filaments also stabilizes their ON state, although it
interacts with myosin head domains with similar affinity,
and also has an inhibitory effect on the thick filament
structure (Pfuhl & Gautel, 2012; Kampourakis et al. 2014;
Mun et al. 2014). The major rearrangement of the myo-
sin heads associated with activation of the thick filament
might disrupt an interaction between cMyBP-C and
myosin heads, promoting a competing activating inter-
action with the thin filament (Kampourakis et al. 2014).
Reciprocal (thin to thick) effects are also possible and
additional mechanisms may contribute to inter-filament
signalling. Thick filament mechano-sensing (Linari et al.
2015), for example, postulates that the regulatory state of
the thick filament is controlled by mechanical stress in the
filament, which is itself a consequence of force generation
and therefore of thin filament activation. This mechanism
would also generate positive co-operativity, but requires a
population ofmyosin heads outside thick filament control
to initiate the positive feedback loop.
Further consideration of the relative significance of
these and other potential mechanisms of interfilament
signalling is likely to require a more detailed under-
standing of the structural basis of the regulatory states
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of the thin and thick filaments, at a level beyond the
simple concept of OFF and ON states. For the thin
filaments, the distinct responses of probes on the cTnC
C and E-helices to BS (Sun et al. 2009; Kampourakis
et al. 2014) provide further support for a concept of thin
filament regulation in the intact sarcomere as a signalling
pathway in which different structural components may
be activated to different extents by the different inputs
to the pathway, including calcium, post-translational
modifications, binding of myosin heads and the actions
of cMyBP-C. Thick filament regulation is also likely
to constitute an analogous multi-component pathway
with multiple inputs for which simple OFF and ON
descriptions are an oversimplification.Moreover, different
regions of the thick filament, for example the C-zone
containing cMyBP-C, are likely to have distinct regulatory
states. Finally, it will be important to extend the pre-
sent consideration of steady-state regulatory states to the
dynamic switching that underlies the cardiac cycle.
Therapeutic mechanism of OM and implications
for drug design
Inherited cardiomyopathies including hypertrophic,
dilated and restricted cardiomyopathy are commonly
linked to mutations in the protein components of the
thick and thin filaments, and filament dysfunction is
a major cause of heart failure (Morita et al. 2010;
McNally et al. 2013). Available treatments for all these
types of heart disease are clearly inadequate, and much
effort continues to be directed towards establishing more
effective therapies with reduced off-target effects. Drugs
that enhance contractility by boosting the calcium trans-
ient suffer from the consequences of the multiple intra-
cellular targets for calcium, and altered calcium handling
can induce arrhythmias. This limitation led to an increased
emphasis on targeting the thick and thin filaments
themselves, initially focused on troponin in the thin
filament, which was perceived to be the primary site
of regulation of contraction (Malik et al. 2011; Radke
et al. 2014; Spudich, 2014; Hwang & Sykes, 2015; Green
et al. 2016). More recently attention has been directed
towards myosin itself (Malik et al. 2011; Radke et al.
2014; Spudich, 2014; Green et al. 2016), and the search
for myosin-targeted therapeutics has been directed by
biochemical and structural models of the interaction
between the myosin head domain, actin and ATP, which
have been used to screen for and characterize the function
of smallmolecules that bind specifically to cardiacmyosin,
and activate (Malik et al. 2011), inhibit (Green et al. 2016),
or restore (Radke et al. 2014) its function. Omecamtiv
mecarbil (OM), the activator used in the present study,
has completed phase II clinical trials for the treatment of
systolic heart failure (Teerlink et al. 2016).
The results presented above showed that, at clinically
relevant concentrations, OM activates cardiac muscle
cells by disrupting the OFF state of the thick filament,
which in turn increases the calcium sensitivity of the thin
filament, producing a large increase in contractility at
physiological calcium concentrations. OM also inhibits
the ATPase activity of myosin and this inhibitory effect
becomes dominant at higher [OM] and [Ca2+]. Both the
activating and inhibitory effects of OM are mediated by
stabilization of a myosin.ADP state, and the therapeutic
window of [OM] and [Ca2+] is created by the intrinsic
co-operativity of the thick and thin filament regulatory
mechanisms.
Our results also suggests a novel approach to the
development of myosin-targeted small molecules that
modulate the contractility of cardiac muscle, either
positively, to enhance the performance of the failing
heart, or negatively, as might be useful in the treatment
of diastolic failure associated with hypertrophic cardio-
myopathy. To supplement the approach of looking for
small molecules like OM and BS that perturb the
actin-myosin ATPase cycle as determined with soluble
myosin fragments that do not form filaments, it might
be possible to design or screen for molecules that perturb
the regulatory state of the thick filament without large
effects on the actin-myosin ATPase (Nogara et al. 2016a).
In principle, and in contrast with OM, such molecules
could be simple activators without competing inhibitory
effects, whichmight facilitate the selection of a therapeutic
dose.
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